ES2524369T3 - Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento - Google Patents

Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento Download PDF

Info

Publication number
ES2524369T3
ES2524369T3 ES10010211.0T ES10010211T ES2524369T3 ES 2524369 T3 ES2524369 T3 ES 2524369T3 ES 10010211 T ES10010211 T ES 10010211T ES 2524369 T3 ES2524369 T3 ES 2524369T3
Authority
ES
Spain
Prior art keywords
constipation
treatment
prostaglandin analogue
dosing unit
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10010211.0T
Other languages
English (en)
Inventor
Ryuji Ueno
Myra L. Patchen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2524369(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Application granted granted Critical
Publication of ES2524369T3 publication Critical patent/ES2524369T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Una unidad de dosificación para uso en el alivio o la prevención del estreñimiento en un paciente humano, que comprende un análogo de prostaglandina (PG) representado por la Fórmula (I) y/o sus tautómeros y un excipiente farmacéuticamente adecuado, donde la unidad de dosificación contiene dicho análogo de PG en una cantidad de aproximadamente 6-72 μg:**fórmula** donde A1 y A2 son los mismos o diferentes átomos de halógeno y B es -COOH, incluyendo sus sales, ésteres o amidas farmacéuticamente aceptables, y donde dicha unidad de dosificación es administrada suficientes veces al día como para que la dosis diaria total del análogo de PG sea de aproximadamente 48-72 μg.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
    imagen2
ES10010211.0T 2001-11-14 2002-11-14 Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento Expired - Lifetime ES2524369T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
US331316P 2001-11-14

Publications (1)

Publication Number Publication Date
ES2524369T3 true ES2524369T3 (es) 2014-12-05

Family

ID=23293447

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02780083T Expired - Lifetime ES2368729T3 (es) 2001-11-14 2002-11-14 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento.
ES10010211.0T Expired - Lifetime ES2524369T3 (es) 2001-11-14 2002-11-14 Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02780083T Expired - Lifetime ES2368729T3 (es) 2001-11-14 2002-11-14 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento.

Country Status (15)

Country Link
US (3) US8097653B2 (es)
EP (2) EP1443938B1 (es)
JP (2) JP4852229B2 (es)
AR (3) AR037524A1 (es)
AT (1) ATE522218T1 (es)
BR (1) BR0214075A (es)
CA (1) CA2464420C (es)
CY (1) CY1115856T1 (es)
DK (2) DK1443938T3 (es)
ES (2) ES2368729T3 (es)
HK (1) HK1155649A1 (es)
LU (1) LU92826I2 (es)
PT (2) PT2298314E (es)
TW (1) TWI331920B (es)
WO (1) WO2003041716A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
JP4705782B2 (ja) * 2002-10-23 2011-06-22 スキャンポ・アーゲー 肥満の処置のためのプロスタグランジン化合物
NZ541110A (en) * 2002-12-27 2008-11-28 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
JP5294559B2 (ja) * 2003-07-03 2013-09-18 スキャンポ・アーゲー クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
JP5241484B2 (ja) * 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5711442B2 (ja) * 2005-04-12 2015-04-30 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
JP5265369B2 (ja) 2006-01-24 2013-08-14 株式会社アールテック・ウエノ 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法
MX2008009650A (es) * 2006-01-24 2008-11-06 R Tech Ueno Ltd Formulacion de capsula de gelatina suave.
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
RU2561873C2 (ru) * 2009-09-18 2015-09-10 Адолор Корпорейшн Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPH0681728B2 (ja) 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
EP0310305B1 (en) * 1987-10-02 1992-07-22 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Cathartics
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
DE69213057T2 (de) * 1991-03-14 1997-01-09 Ueno Seiyaku Oyo Kenkyujo Kk Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
DK0554794T3 (da) * 1992-02-04 1999-04-26 Eisai Co Ltd Aminobenzoesyrederivater
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
JP3187438B2 (ja) * 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
ATE401894T1 (de) 1997-11-28 2008-08-15 Sucampo Ag Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
HU230484B1 (hu) 1999-10-15 2016-07-28 Sucampo Ag Egy biciklusos vegyületet és egy gliceridet tartalmazó új kompozíció
NZ521784A (en) 2000-04-06 2005-04-29 Sucampo Ag Bile secretion promoting composition
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
JP4597481B2 (ja) 2001-05-18 2010-12-15 スキャンポ・アーゲー 下剤組成物
MXPA04002006A (es) 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
NZ541110A (en) 2002-12-27 2008-11-28 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
JP2005513014A (ja) 2005-05-12
JP4852229B2 (ja) 2012-01-11
HK1155649A1 (en) 2012-05-25
BR0214075A (pt) 2004-09-28
US20120088824A1 (en) 2012-04-12
DK2298314T3 (en) 2014-12-01
EP1443938A1 (en) 2004-08-11
US20130143958A1 (en) 2013-06-06
US8097653B2 (en) 2012-01-17
WO2003041716A1 (en) 2003-05-22
US8389542B2 (en) 2013-03-05
JP2011201905A (ja) 2011-10-13
TW200300091A (en) 2003-05-16
CY1115856T1 (el) 2017-01-25
EP1443938B1 (en) 2011-08-31
ATE522218T1 (de) 2011-09-15
CA2464420C (en) 2011-12-13
EP2298314A1 (en) 2011-03-23
CA2464420A1 (en) 2003-05-22
ES2368729T3 (es) 2011-11-21
LU92826I2 (fr) 2015-11-24
AR117404A2 (es) 2021-08-04
US20030119898A1 (en) 2003-06-26
DK1443938T3 (da) 2011-09-26
PT2298314E (pt) 2014-12-03
EP2298314B1 (en) 2014-09-03
TWI331920B (en) 2010-10-21
AR098997A2 (es) 2016-06-22
AR037524A1 (es) 2004-11-17
PT1443938E (pt) 2011-09-27

Similar Documents

Publication Publication Date Title
ES2524369T3 (es) Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
NO20055880L (no) Memantin orale doseringsformer
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
ES2176436T3 (es) Nueva forma de dosificacion farmaceutica oral.
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
DE69225421D1 (de) Sumatriptan enthaltende Arzneimittel
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
AR039335A1 (es) Tableta de carga de droga alta
AR029174A1 (es) Derivados de espirooxindol, proceso para su preparacion, formulacion farmaceutica, y utilizacion de los derivados en la manufactura de medicamentos
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
MX9203444A (es) Medicamentos.
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
AR045161A1 (es) Derivados de quinazolina
CR9842A (es) Composiciones de celecoxib
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina